Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Shares Outstanding (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Shares Outstanding data on record, last reported at $126.6 million in Q4 2025.

  • For Q4 2025, Shares Outstanding rose 1.71% year-over-year to $126.6 million; the TTM value through Dec 2025 reached $126.6 million, up 1.71%, while the annual FY2025 figure was $126.6 million, 1.71% up from the prior year.
  • Shares Outstanding reached $126.6 million in Q4 2025 per APLS's latest filing, roughly flat from $126.5 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $126.6 million in Q4 2025 and bottomed at $87219.0 in Q3 2021.
  • Average Shares Outstanding over 5 years is $108.0 million, with a median of $118.0 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding: surged 115125.78% in 2021, then grew 1.71% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $97.5 million in 2021, then rose by 13.58% to $110.8 million in 2022, then increased by 7.93% to $119.6 million in 2023, then increased by 4.13% to $124.5 million in 2024, then rose by 1.71% to $126.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding were $126.6 million in Q4 2025, $126.5 million in Q3 2025, and $126.2 million in Q2 2025.